Sugi Predict

Sugi Predict / Compounds / SCHEMBL613545

SCHEMBL613545

SCHEMBL613545

COC(=O)c1cccc(OCCNC(=O)OC(C)(C)C)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.53
▸ CA1 P00915 3/20 0.53
▸ CA2 P00918 3/20 0.53
▸ CA9 Q16790 3/20 0.53
▸ PDK2 Q15119 1/20 0.52
▸ MTNR1A P48039 1/20 0.50
▸ MTNR1B P49286 1/20 0.50
▸ ALDH1A1 P00352 2/20 0.49
▸ F10 P00742 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ POLB P06746 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ MRGPRX4 Q96LA9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29410763 1.00 CA12 (0.53) CA12CA1CA2CA9PDK2
SCHEMBL8457822 0.96 CA12 (0.54) CA12CA1CA2CA9PDK2
SCHEMBL6435296 0.93 CA12 (0.49) CA12CA1CA2CA9PDK2
SCHEMBL15360324 0.93 BCHE (0.51) CA12CA1CA2CA9PDK2
SCHEMBL613521 0.89 KMT2A (0.58) CA12CA1CA2CA9PDK2
SCHEMBL31539418 0.89 KMT2A (0.58) CA12CA1CA2CA9PDK2
SCHEMBL4080429 0.88 MRGPRX4 (0.46) MTNR1AMTNR1BALDH1A1NPC1RAB9A
SCHEMBL5779176 0.87 CA12 (0.54) CA12CA1CA2CA9PDK2
SCHEMBL13191680 0.87 CA12 (0.54) CA12CA1CA2CA9PDK2
SCHEMBL6478753 0.86 CA12 (0.55) CA12CA1CA2CA9PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025054132-A1 ANTIBACTERIAL COMPOUNDS ARREPATH, INC. (US) 2025-03-13 — — WO disclosed
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2025-01-30 — — US disclosed
US-12134609-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-11-05 — — US disclosed
US-20240092760-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2024-03-21 — — US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed
EP-4234551-A2 PYRIDAZINONES AS PARP7 INHIBITORS Ribon Therapeutics Inc. (US) 2023-08-30 — — EP disclosed
EP-4208452-A1 QUINOLINE CGAS ANTAGONIST COMPOUNDS Immunesensor Therapeutics, Inc. (US) 2023-07-12 — — EP disclosed
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2023-06-22 — — US disclosed
US-8076516-B2 Amine derivative compounds for treating ophthalmic diseases and disorders ACUCELA, INC. (US) 2011-12-13 — — US disclosed
US-20090281149-A1 Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders ACUCELA, INC. (US) 2009-11-12 — — US disclosed
EP-2111223-A1 AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS Acucela, Inc. (US) 2009-10-28 — — EP disclosed
WO-2009058216-A1 AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA, INC. (US) 2009-05-07 — — WO disclosed
US-7304077-B2 Chemical compounds ASTRAZENECA AB (SE) 2007-12-04 — — US disclosed
US-20040102432-A1 Chemical compounds ASTRAZENECA AB (SE) 2004-05-27 — — US disclosed
EP-1322611-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2003-07-02 — — EP disclosed
WO-2002020484-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2002-03-14 — — WO disclosed
US-5739163-A ANTICOAGULANTS THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-04-14 — — US disclosed
US-5523302-A ANTICOAGULANTS, CARDIOVASCULAR DISORDERS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-06-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092760-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS CA12 3267/4885CA1 3083/4885CA2 1016/4885
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 CA12 4842/4885CA1 4884/4885CA2 4795/4885
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS CA12 3267/4885CA1 3083/4885CA2 1016/4885
US-12134609-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS CA12 3267/4885CA1 3083/4885CA2 1016/4885
US-20040102432-A1 Chemical compounds CCL11, HRH1, HRH4 CA12 1272/4885CA1 1478/4885CA2 762/4885
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 CA12 4842/4885CA1 4884/4885CA2 4795/4885
US-20090281149-A1 Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders PDE6D, CLN6, AADAT CA12 4153/4885CA1 4855/4885CA2 3441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.